You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mCRPC

Showing 1 - 25 of 515
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Trial (TmPSMA-02 CAR T Cells)

Not yet recruiting
  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
  • TmPSMA-02 CAR T Cells
  • (no location specified)
Sep 13, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Prostatic Neoplasms
  • (no location specified)
Nov 21, 2023

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial (MK-5684, Dexamethasone, Fludrocortisone acetate)

Not yet recruiting
  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer
  • (no location specified)
Oct 23, 2023

Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC Trial (INKmune)

Not yet recruiting
  • Cancer
  • +2 more
  • INKmune
  • (no location specified)
Sep 27, 2023

Hormone-refractory Prostate Cancer Trial (AMX-500)

Not yet recruiting
  • Hormone-refractory Prostate Cancer
  • (no location specified)
Aug 11, 2023

Prostate Cancer Metastatic Trial (MK-5684, Abiraterone acetate, Enzalutamide)

Not yet recruiting
  • Prostate Cancer Metastatic
  • (no location specified)
Nov 21, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Disitamab Vedotin(RC48-ADC))

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Disitamab Vedotin（RC48-ADC）
  • (no location specified)
Jul 13, 2023

Metastasis Castration Resistant Prostate Cancer(mCRPC) Trial (HS-20093)

Not yet recruiting
  • Metastasis Castration Resistant Prostate Cancer(mCRPC)
  • (no location specified)
Aug 14, 2023

Castration-Resistant Prostatic Cancer Trial ([Lu-177]-PNT2002)

Available
  • Castration-Resistant Prostatic Cancer
  • (no location specified)
Sep 11, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 2, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)

No longer available
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 12, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Prostate Cancer Trial in Long Beach, West Los Angeles, Hines (stereotactic ablative radiotherapy, Pluvicto, topical

Not yet recruiting
  • Prostate Cancer
  • stereotactic ablative radiotherapy
  • +2 more
  • Long Beach, California
  • +2 more
Oct 13, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in Bellinzona, London Borough of Sutton (Enzalutamide 40mg,

Recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Enzalutamide 40mg
  • +4 more
  • Bellinzona, Switzerland
  • +1 more
Nov 6, 2023

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Prostate Cancer, mCRPC Trial in Seoul (Lu-177-DGUL, Ga-68-NGUL)

Recruiting
  • Prostate Cancer
  • mCRPC
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 22, 2022

Metastatic Castration-resistant Prostate Cancer Trial (TmPSMA-02)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TmPSMA-02
  • (no location specified)
Aug 3, 2022

Prostate Cancer Trial in Beijing (2.0 GBq of 177Lu-EB-PSMA)

Recruiting
  • Prostate Cancer
  • 2.0 GBq of 177Lu-EB-PSMA
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jul 13, 2022

Prostate Cancer Trial in Boston (Radium-223, Pembrolizumab)

Active, not recruiting
Has Results
  • Prostate Cancer
  • Boston, Massachusetts
  • +1 more
Aug 31, 2022

Metastatic Castrate-resistant Prostate Cancer, mCRPC Trial in Dallas (Sipuleucel-T, Stereotactic Ablative Body Radiation)

Completed
Has Results
  • Metastatic Castrate-resistant Prostate Cancer
  • mCRPC
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Apr 11, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (Sipuleucel-T Injection)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Sipuleucel-T Injection
  • (no location specified)
Nov 10, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Bellinzona, Chur, St. Gallen (Docetaxel micellar)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Docetaxel micellar
  • Bellinzona, Switzerland
  • +2 more
Nov 7, 2022

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Advanced Prostate Cancer Trial (HRS-5041)

Not yet recruiting
  • Advanced Prostate Cancer
  • (no location specified)
Jul 5, 2023